JP2025504625A - 二重結合特異性を有する設計された反復ドメイン及びその使用 - Google Patents

二重結合特異性を有する設計された反復ドメイン及びその使用 Download PDF

Info

Publication number
JP2025504625A
JP2025504625A JP2024534166A JP2024534166A JP2025504625A JP 2025504625 A JP2025504625 A JP 2025504625A JP 2024534166 A JP2024534166 A JP 2024534166A JP 2024534166 A JP2024534166 A JP 2024534166A JP 2025504625 A JP2025504625 A JP 2025504625A
Authority
JP
Japan
Prior art keywords
repeat
repeat domain
target
designed
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504625A5 (https=
Inventor
ジーモン フォンテーヌ
アンドレアス ボスハルト
ベルント シュレーレス
ダニエル シュタイナー
マルセル ヴァルザー
Original Assignee
モレキュラー パートナーズ アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー パートナーズ アクチェンゲゼルシャフト filed Critical モレキュラー パートナーズ アクチェンゲゼルシャフト
Publication of JP2025504625A publication Critical patent/JP2025504625A/ja
Publication of JP2025504625A5 publication Critical patent/JP2025504625A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024534166A 2021-12-14 2022-12-14 二重結合特異性を有する設計された反復ドメイン及びその使用 Pending JP2025504625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21214519 2021-12-14
EP21214519.7 2021-12-14
PCT/EP2022/085794 WO2023110983A1 (en) 2021-12-14 2022-12-14 Designed repeat domains with dual binding specificity and their use

Publications (2)

Publication Number Publication Date
JP2025504625A true JP2025504625A (ja) 2025-02-14
JP2025504625A5 JP2025504625A5 (https=) 2025-12-17

Family

ID=80112165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534166A Pending JP2025504625A (ja) 2021-12-14 2022-12-14 二重結合特異性を有する設計された反復ドメイン及びその使用

Country Status (9)

Country Link
US (1) US20250042957A1 (https=)
EP (1) EP4447990A1 (https=)
JP (1) JP2025504625A (https=)
KR (1) KR20240122764A (https=)
CN (1) CN118354784A (https=)
AU (1) AU2022413461A1 (https=)
CA (1) CA3239407A1 (https=)
IL (1) IL313411A (https=)
WO (1) WO2023110983A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
WO2025050026A1 (en) * 2023-08-30 2025-03-06 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides for inducible and repressible binding to targets of interest and methods of use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025146487A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Multispecific binding proteins
WO2025146490A1 (en) * 2024-01-05 2025-07-10 Molecular Partners Ag Recombinant cd117 binding proteins and their use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US8492122B2 (en) 2002-03-11 2013-07-23 The Johns Hopkins University Molecular switches and methods for making and using the same
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
PL2643349T3 (pl) 2010-11-26 2020-03-31 Molecular Partners Ag Zaprojektowane białka z powtórzeniami wiążące się z albuminą surowicy
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
WO2015067302A1 (en) 2013-11-05 2015-05-14 Ecole Polytechnique Federale De Lausanne (Epfl) Sensor molecules and uses thereof
KR102427117B1 (ko) 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
US11261250B2 (en) * 2016-07-22 2022-03-01 Fred Hutchinson Cancer Research Center Bi-specific molecule for cell-specific Notch inhibition and related methods and compositions
CN109790206A (zh) 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
US12049482B2 (en) 2017-10-31 2024-07-30 The Brigham And Women's Hospital, Inc. Molecular switch-mediated control of engineered cells
WO2020190852A2 (en) 2019-03-17 2020-09-24 Jorge Fallas Topological control of receptor signaling using synthetic homo- and hetero-dimeric cytokine mimetics
IL293698A (en) 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
US20240279290A1 (en) * 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
AU2021403658A1 (en) 2020-12-16 2023-06-29 Molecular Partners Ag Recombinant cd3 binding proteins and their use

Also Published As

Publication number Publication date
AU2022413461A1 (en) 2024-06-06
KR20240122764A (ko) 2024-08-13
WO2023110983A1 (en) 2023-06-22
US20250042957A1 (en) 2025-02-06
EP4447990A1 (en) 2024-10-23
CA3239407A1 (en) 2023-06-22
CN118354784A (zh) 2024-07-16
IL313411A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
JP2025504625A (ja) 二重結合特異性を有する設計された反復ドメイン及びその使用
ES2981441T3 (es) Proteínas de repetición diseñadas que se unen a la seroalbúmina
JP6486908B2 (ja) 肝細胞増殖因子に結合する設計アンキリン反復タンパク質
AU2016295024B2 (en) Her2 binding proteins based on di-ubiquitin muteins
CN113164593A (zh) 兽用抗il4受体抗体
JP6738340B2 (ja) 新規なｅｇｆｒ結合タンパク質
US11136400B2 (en) Anti-EphA4 antibody
US11156608B2 (en) Method for the site-specific covalent cross-linking of antibodies to surfaces
JP2023518952A (ja) 獣医用抗ｉｌ４受容体抗体
JP2023537958A (ja) Ｂｃｍａと結合する単一可変ドメイン及び抗原結合分子
KR20230162790A (ko) 항-타우 항체 및 이의 용도
TW201102086A (en) Antibodies against human CCN1 and uses thereof
JP7518771B2 (ja) 抗ｃｄ９９ダイアボディ又はｉｇｇ抗体及びそれらの使用
JP7814714B2 (ja) ロイシンリッチリピートキナーゼ２のアロステリック調節因子
KR20240099394A (ko) 신규한 Nav1.7 모노클로날 항체
WO2025146491A1 (en) Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
CN118085081B (zh) 一种特异性结合vegf的纳米抗体及用途
KR102909686B1 (ko) Lpa 수용체에 대한 고 친화성 항체의 개발
JP7851924B2 (ja) 抗ｔｒｏｐ－２抗体、その抗原結合断片又はその変異体、及びそれらの医学的使用
EP4299124A1 (en) Anti-mglur2 nanobodies for use as biomolecule transporter
WO2025146490A1 (en) Recombinant cd117 binding proteins and their use
JP2025533157A (ja) ２価のｃｄ４７結合タンパク質
KR20230145939A (ko) 케모카인 수용체 cxcr4에 대한 고 친화성 항체
HK40059771A (en) Designed repeat proteins binding to serum albumin
HK40059387A (en) Anti-il4 receptor antibodies for veterinary use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251208